Discontinued — last reported Q4 '25
Operating Expenses
Finance Lease ROU Asset Amortization
Vertex Pharmaceuticals Finance Lease ROU Asset Amortization remained flat by 0.0% to $1.80M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 76.7%, from $7.73M to $1.80M. Over 2 years (FY 2023 to FY 2025), Finance Lease ROU Asset Amortization shows a downward trend with a -58.9% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2019
Last reportedQ4 2025
How to read this metric
Changes reflect the company's strategy regarding capital asset acquisition versus leasing.
Detailed definition
This represents the non-cash expense related to the systematic write-down of right-of-use assets acquired through financ...
Peer comparison
Standard disclosure under ASC 842 lease accounting requirements.
Metric ID:
msft_finance_lease_right_of_use_asset_amortizationHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $42.70M | $30.90M | $7.20M |
| YoY Change | — | -27.6% | -76.7% |
Range$7.20M – $42.70M
CAGR-58.9%
Avg YoY Growth-52.2%
Median YoY Growth-52.2%
Current Streak2+ years decline
Finance Lease ROU Asset Amortization at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's finance lease rou asset amortization?
- Vertex Pharmaceuticals (VRTX) reported finance lease rou asset amortization of $1.80M in Q4 2025.
- How has Vertex Pharmaceuticals's finance lease rou asset amortization changed year-over-year?
- Vertex Pharmaceuticals's finance lease rou asset amortization decreased by 76.7% year-over-year, from $7.73M to $1.80M.
- What is the long-term trend for Vertex Pharmaceuticals's finance lease rou asset amortization?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's finance lease rou asset amortization has grown at a -58.9% compound annual growth rate (CAGR), from $42.70M to $7.20M.
- What does finance lease rou asset amortization mean?
- The periodic expense for the usage of assets held under finance leases.